Table 3 Preoperative markers, bcl-2 and cathepsin–L serum concentrations depending on the method of treatment at serous tumors only
Primary optimal cytoreduction | Neoadjuvant chemotherapy | p | |
|---|---|---|---|
CA125 [IU/ml] | |||
Mean | 455.1 | 2661.46 | |
Median | 167.25 | 600.0 | p = 0.0019 |
Range | (15.81-2377.0) | (49.22-22982.0) | |
HE4 [pmol/l] | |||
Mean | 87.62 | 560.7 | |
Median | 24.78 | 564.72 | p = 0.0009 |
Range | (2.5-775.79) | (45.82-1310.69) | |
YKL-40 [ng/ml] | |||
Mean | 128.73 | 203.37 | |
Median | 84.23 | 200.24 | p = 0.005 |
Range | (16.42-417.27) | (45.02-437.01) | |
Cathepsin-L [ng/ml] | |||
Mean | 12.95 | 12.81 | |
Median | 84.23 | 10.98 | p = 0.8125 |
Range | (8.42-28.87) | (8.53-46.45) | |
bcl-2 [ng/ml] | |||
Mean | 12.01 | 23.98 | |
Median | 20.98 | 20.07 | p = 0.6913 |
Range | (11.27-45.53) | (4.88-81.02) |